Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial
International Journal of Eating Disorders · 2025
DOI: 10.1002/eat.24502 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Eating Disorders, 2025. Verfasst von Carlos M Grilo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Cognitive Behavioral Therapy, Binge-Eating Disorder, Central Nervous System Stimulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Objective
A 12‐week randomized controlled trial (RCT) found cognitive‐behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT + LDX showed significant improvements in BED, with combined CBT + LDX being superior to the individual treatments. This report details the treatment effects on secondary outcomes comprising behavioral, psychological, and metabolic variables intended to build on the primary outcomes to broaden our understanding of BED treatment.
Method
RCT randomized N = 141 patients with BED to one of three 12‐week treatments: CBT ( N = 47), LDX ( N = 47), or CBT + LDX ( N = 47). 87.2% completed posttreatment assessments.
Results
Mixed models revealed significant decreases in eating (food cravings and hedonic drive to eat palatable foods) and metabolic (cholesterol and triglycerides) variables in all treatments, with CBT + LDX having the largest reduction and significantly outperforming CBT and LDX. Overvaluation of shape/weight and impulsivity decreased significantly in all treatments but did not differ significantly between treatments. Delayed discounting did not change overall during treatment nor show an interaction with specific treatments.
Conclusions
Significant improvements in secondary outcomes in this RCT for BED suggest CBT and LDX, and particularly their combination, are associated with broad positive effects beyond their significant effects on binge eating. Future research should examine moderator/mediational effects of these variables on differential treatment responses in BED. Clinicaltrials.gov Registration: NCT03924193 (Cognitive‐Behavioral and Pharmacologic (LDX) Treatment of Binge‐Eating Disorder and Obesity: Acute Treatment).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
ORCID-Profile: Carlos M Grilo, Valentina Ivezaj, Sydney Yurkow, Cenk Tek, Ralitza Gueorguieva
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Grilo, C. M., Ivezaj, V., Yurkow, S., Tek, C., & Gueorguieva, R. (2025). Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial. International Journal of Eating Disorders. https://doi.org/10.1002/eat.24502
Vancouver
Grilo CM, Ivezaj V, Yurkow S, Tek C, Gueorguieva R. Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial. International Journal of Eating Disorders. 2025. doi:10.1002/eat.24502
BibTeX
@article{Grilo2025,
author = {Grilo, Carlos M and Ivezaj, Valentina and Yurkow, Sydney and Tek, Cenk and Gueorguieva, Ralitza},
title = {Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial},
journal = {International Journal of Eating Disorders},
year = {2025},
doi = {10.1002/eat.24502}
}
EUVIMED